KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Receivables: 2020-2025

Historic Change in Receivables for Aurinia Pharmaceuticals (AUPH) over the last 6 years, with Sep 2025 value amounting to -$9.4 million.

  • Aurinia Pharmaceuticals' Change in Receivables fell 185.42% to -$9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.8 million, marking a year-over-year decrease of 293.37%. This contributed to the annual value of $12.5 million for FY2024, which is 17.43% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Change in Receivables of -$9.4 million as of Q3 2025, which was down 3,515.06% from -$259,000 recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Change in Receivables peaked at $23.6 million during Q3 2022, and registered a low of -$28.3 million during Q4 2022.
  • In the last 3 years, Aurinia Pharmaceuticals' Change in Receivables had a median value of $457,000 in 2023 and averaged $1.6 million.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Change in Receivables spiked by 3,431.48% in 2021 and then slumped by 841.14% in 2024.
  • Aurinia Pharmaceuticals' Change in Receivables (Quarterly) stood at $5.6 million in 2021, then plummeted by 605.05% to -$28.3 million in 2022, then surged by 51.01% to -$13.9 million in 2023, then surged by 100.44% to $61,000 in 2024, then plummeted by 185.42% to -$9.4 million in 2025.
  • Its Change in Receivables was -$9.4 million in Q3 2025, compared to -$259,000 in Q2 2025 and $3.8 million in Q1 2025.